11/5/2020 · This analysis describes periprocedural interruption of edoxaban in real world EMIT AF/VTE study. Methods: EMIT AF/VTE was a prospective, non-interventional study conducted in 7 European countries that collected detailed information on periprocedural management of edoxaban from 5 days before to 30 days after procedure in patients with AF or VTE.
This observational prospective registry called “EMIT-AF/VTE : Edoxaban management in diagnostic and therapeutic procedures” is observing patients taking edoxaban (marketed as Lixiana) in a real life setting. Edoxaban is a non-VKA oral anti-coagulant (NOAC) that is prescribed to patients with Atrial Fibrillation (AF) to minimise the risk of stroke or …
In the EMIT-AF/VTE study, the number of bleeding and thromboembolic events in patients treated with edoxaban undergoing elective or unplanned procedures was low either in Italy or in the rest of Europe. The safety and efficacy of edoxaban was confirmed in Italy even if patients were older, presented.
3/19/2019 · EMIT – AF /VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural management and outcomes. It is the first large prospective, non-interventional study to.
10/31/2016 · Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R, Chen C, Colonna P. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF .
3/19/2019 · MUNICH, March 19, 2019 /PRNewswire/ — In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® ( edoxaban ) use in clinical practice. EMIT – AF /VTE is one of the first sets of data to be presented EMIT – AF /VTE, 3/19/2019 · The EMIT – AF /VTE study is part of the Edoxaban Clinical Research Programme that, in 2019, will deliver significant evidence to support the use of edoxaban in clinical practice, particularly for …
3/19/2019 · Data from the Non-interventional EMIT – AF /VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF /VTE Patients.
1/1/2021 · So far, the only available data for edoxaban periprocedural management come from the ENGAGE AF-TIMI 48 trial. The recently published EMIT-AF/VTE study showed low periprocedural bleeding and thromboembolic risks of edoxaban in a real-world setting in patients undergoing any diagnostic or therapeutic procedures.
EMIT – AF /VTE is the first large observational, multicentre, multinational study on peri-procedural management and outcomes of edoxaban . It is the first large, single NOAC-prospective, non-interventional study to apply the EHRA peri-procedural bleeding risk classification, which was introduced in April 2018,(1) in a routine clinical practice setting.
